 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LM-101 / LaNova Medicines Limited
Primary analysis of a phase 1/2 study of LM-101: An anti-SIRP? antibody as a single agent in patients with advanced malignancies. (Hall A; Poster Bd #: 119) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3041;
P1/2
LM-101 monotherapy showed excellent safety profile and promising anti-tumor activity in patients with advanced malignancies. Further investigation of LM-101 as a single agent and in combination with other anti-tumor agents are ongoing.
- LM-101 / LaNova Medicines Limited
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LM101-01-103: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=145, Suspended, Sponsor: LaNova Medicines Limited
- ||||| LM-101 / LaNova Medicines Limited
Trial suspension, Combination therapy, Metastases: LM101-01-103: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Nov 19, 2023
P1/2, N=145, Suspended, Sponsor: LaNova Medicines Limited
Further investigation of LM-101 as a single agent and in combination with other anti-tumor agents are ongoing. Recruiting --> Suspended
- ||| LM-101 / LaNova Medicines Limited
Enrollment open, Combination therapy, IO biomarker, Metastases: LM101-01-103: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Jan 19, 2023
P1/2, N=145, Recruiting, Sponsor: LaNova Medicines Limited
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| LM-101 / LaNova Medicines Limited
New P1/2 trial, Combination therapy, IO biomarker, Metastases: LM101-01-103: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Nov 14, 2022
P1/2, N=145, Not yet recruiting, Sponsor: LaNova Medicines Limited